As ultra-large-scale virtual screening becomes critical for early-stage drug discovery, highly efficient screening methods are gaining prominence. Deep-learning-based approaches which directly estimate binding affinities without binding conformation have attracted great attention as an alternative solution to molecular docking, but the generalization capability of existing methods in vast chemical space remains uncertain due to restricted training data. Here, we introduce PharmacoNet, the first deep-learning framework for pharmacophore modeling toward ultra-fast virtual screening. PharmacoNet offers fully automated protein-based pharmacophore modeling and evaluates the potency of ligands with a parameterized analytical scoring function, ensuring high generalization ability across unseen targets and ligands. Our benchmark study shows that PharmacoNet is extremely fast yet reasonably accurate compared to traditional docking methods and existing deep learning-based scoring models. We successfully identified selective inhibitors from 187 million compounds against cannabinoid receptors within 21 hours on a single CPU. This study uncovers the hitherto untapped potential of deep learning in pharmacophore modeling.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575537 | PMC |
http://dx.doi.org/10.1039/d4sc04854g | DOI Listing |
J Cheminform
January 2025
Oxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford, UK.
Current strategies centred on either merging or linking initial hits from fragment-based drug design (FBDD) crystallographic screens generally do not fully leaverage 3D structural information. We show that an algorithmic approach (Fragmenstein) that 'stitches' the ligand atoms from this structural information together can provide more accurate and reliable predictions for protein-ligand complex conformation than general methods such as pharmacophore-constrained docking. This approach works under the assumption of conserved binding: when a larger molecule is designed containing the initial fragment hit, the common substructure between the two will adopt the same binding mode.
View Article and Find Full Text PDFDrug Discov Today
January 2025
State Key Laboratory of Digestive Health, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050 China; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050 China. Electronic address:
Metalloenzymes are important therapeutic targets for a variety of human diseases. Computational approaches have recently emerged as effective tools to understand metal-ligand interactions and expand the structural diversity of both metalloenzyme inhibitors (MIs) and metal-binding pharmacophores (MBPs). In this review, we highlight key advances in currently available fine-tuning modeling methods and data-driven cheminformatic approaches.
View Article and Find Full Text PDFPLoS One
January 2025
Vista Aria Rena Gene Inc., Gorgan, Golestan, Iran.
Due to its global burden, Targeting Hepatitis B virus (HBV) infection in humans is crucial. Herbal medicine has long been significant, with flavonoids demonstrating promising results. Hence, the present study aimed to establish a way of identifying flavonoids with anti-HBV activities.
View Article and Find Full Text PDFOrganoselenocyanates have attracted considerable attention in recent years due to their therapeutic potential and versatility in medicinal chemistry. Here, we report on the mechanism of inhibition by 5-phenylcarbamoylpentyl selenocyanide (SelSA-2), an analogue of the well-characterized histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA, a.k.
View Article and Find Full Text PDFArch Pharm (Weinheim)
January 2025
Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic.
The Takeda G protein-coupled receptor 5 (TGR5), also known as GPBAR1 (G protein-coupled bile acid receptor), is a membrane-type bile acid receptor that regulates blood glucose levels and energy expenditure. These essential functions make TGR5 a promising target for the treatment of type 2 diabetes and metabolic disorders. Currently, most research on developing TGR5 agonists focuses on modifying the structure of bile acids, which are the endogenous ligands of TGR5.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!